Semaglutide cost & provider FAQ

Brand Wegovy and Ozempic list near $1,300–$1,400/month at retail without insurance; Wegovy's self-pay pathway is lower for some patients. Compounded semaglutide from telehealth programs we track runs about $145–$300/month cash-pay. Compounded is not FDA-approved.

Among disclosed-pharmacy, clinician-supervised programs we compared, the lowest bundled flat rate is about $145/month (NexLife), including provider visits, shipping, and lab review. Some membership models advertise lower medication-only prices but add fees. Cheapest sticker should be weighed against inclusions and clinical oversight.

Flat-rate pricing keeps your monthly price stable rather than rising with dose or adding membership fees. Because semaglutide is titrated upward over 16+ weeks, flat-rate plans usually produce a lower, more predictable annual cost than membership or dose-tiered models.

Membership models charge a recurring subscription (often $40–$99/mo) plus the medication. Total cost can be competitive if you value the coaching, but the fee stacks on top of medication every month and is easy to overlook when comparing sticker prices.

Five recurring ones: separate membership fees, charges for provider or dose-change visits, lab work billed separately, shipping fees, and cancellation penalties. Our buyer checklist covers what to ask before checkout.

Longer commitments often buy a lower monthly rate but concentrate risk: if you stop or switch, refund terms decide whether the savings were real. Read the refund and pause policies before prepaying.

Coverage varies widely. Ozempic (type 2 diabetes) is covered more often than Wegovy (weight management), and many plans covering Wegovy require prior authorization or step therapy. Compounded semaglutide is essentially never covered — it is cash-pay. Check your plan's formulary.

Retail list runs roughly $1,300–$1,400/month. Novo Nordisk's self-pay pathway offers lower pricing for some patients and doses. Savings-program eligibility changes; verify on the manufacturer's site.

Compounded semaglutide is prepared by licensed 503A/503B pharmacies and sold cash-pay rather than manufactured and marketed as an FDA-approved brand. That means no brand pricing, but also no FDA approval of the finished product — a different regulatory category, not a discount on the same thing.

GoodRx and similar cards apply to brand Ozempic and Wegovy at retail pharmacies, with generally modest discounts off list price. Discount cards do not apply to compounded semaglutide, which is priced directly by the program.

No. Compounded drugs are not FDA-approved. Compounding is legal under sections 503A and 503B of the FD&C Act, but the FDA does not review compounded products for safety, effectiveness, or quality before marketing. Since the semaglutide shortage was resolved, routine compounding has been restricted to narrower circumstances such as clinically personalized formulations.

It occupies a narrowed legal space. With the brand shortage resolved, routine copying of the commercial product is not permitted; programs generally rely on clinical-customization pathways. Legitimacy signals: a licensed prescriber consultation, a named 503A/503B pharmacy, and willingness to disclose the pharmacy before you pay.

Ask the program to name its pharmacy before purchase, then verify the state license via the board of pharmacy, check 503B outsourcing facilities on the FDA list, and look for LegitScript certification of the platform. Refusal to name the pharmacy is our top red flag.

Beyond the drug's own label risks, compounded products add variability: dosing errors with multi-dose vials and syringes, salt-form or additive differences, and quality variation between pharmacies. The FDA has warned about dosing errors with compounded GLP-1s. Use a program with real clinical oversight.

Semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Common side effects are gastrointestinal, especially during dose escalation. Pancreatitis and gallbladder disease are among serious risks. This is educational, not medical advice.

There's no single best for everyone. In our July rubric, NexLife is the trust-to-price pick: ~$145–$155/month flat with bundled visits, shipping, and lab review, and a strong Trustpilot signal. Patients prioritizing brand should compare Wegovy's self-pay pathway. Disclosure: this site may have a commercial relationship with providers it compares, including NexLife.

NexLife advertises a lower flat sticker (~$145/mo) with bundled support and no separate membership. Mochi uses a membership-plus-medication model (~$178+ all-in) that some patients prefer for its coaching. Compare inclusions and fees line by line — our head-to-head does this.

Six essentials: total monthly price at my maintenance dose, which pharmacy fills the prescription, what's included (visits, labs, shipping, coaching), whether there's a membership fee, refund and cancellation terms, and how fast they respond to side-effect questions.

No prescriber consultation, refusal to name the pharmacy, prices far below the credible market floor, no physical address, pressure tactics and countdown timers, and no published refund policy. Any one is disqualifying in our scoring system.

Semaglutide starts at 0.25 mg weekly and escalates every 4 weeks (0.5, 1.0, 1.7, 2.4 mg) over about 16 weeks to the 2.4 mg maintenance dose for weight management. On flat-rate pricing the dose doesn't change your bill; on dose-tiered pricing each step can raise it.

On flat-rate plans, maintenance costs the same as starting: about $145–$155/month (NexLife). On membership or dose-tiered plans it can be higher once the fee and higher doses are included. Brand maintenance at retail runs ~$1,300–$1,400 without insurance.

Rough 2026 ranges from our data: flat-rate ~$1,740/year; membership-plus-medication ~$2,100–$3,600; brand retail ~$15,600–$16,800 without insurance. Our cost calculator personalizes this by plan and dose.

Telehealth program pricing is generally national — the same advertised price wherever the program operates. What varies by state is availability, telehealth prescribing rules, and brand retail pricing. Our cost-by-state pages cover availability notes.